Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199465 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
A Phase 1 study of Cytomegalovirus Prophylaxis, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 10
- Study locations
NCT07199465: Recruiting Phase 1 study of Cytomegalovirus Prophylaxis, sponsored by Merck Sharp & Dohme.
NCT07199465 is a Phase 1 study of Cytomegalovirus Prophylaxis that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07199465, a Phase 1 study of Cytomegalovirus Prophylaxis, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 10
- Study locations
Study Summary
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if participants tolerate it
Primary Outcome
Blood samples will be collected at multiple time points to estimate AUC0-24
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (10)
California
- UCLA Clinical & Translational Research Center (CTRC) ( Site 0006) - Los Angeles
- Lucile Packard Children's Hospital ( Site 0001) - Palo Alto
- University of California Davis Health ( Site 0023) - Sacramento
- UCSF Medical Center at Mission Bay ( Site 0017) - San Francisco
Colorado
- Children's Hospital Colorado ( Site 0013) - Aurora
Michigan
- University of Michigan ( Site 0014) - Ann Arbor
Minnesota
- Mayo Clinic - Rochester ( Site 0015) - Rochester
New York
- Morgan Stanley Children's Hospital ( Site 0018) - New York
North Carolina
- Duke University Medical Center ( Site 0008) - Durham
Ohio
- Cincinnati Children's Hospital Medical Center ( Site 0002) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-24 |
| Est. Completion | 2028-05-19 |
| Phase | Phase 1 |
What NCT07199465 shows while recruiting
NCT07199465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Cytomegalovirus Prophylaxis appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT07199465 lists 10 locations in 7 states (California, Colorado, Michigan).
Frequently Asked Questions
What is clinical trial NCT07199465 about?
NCT07199465 is a clinical study titled "A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)". Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of let...
What is the current status of trial NCT07199465?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-04-24. Estimated completion is 2028-05-19.
What conditions does trial NCT07199465 study?
This clinical trial studies the following conditions: Cytomegalovirus Prophylaxis.
What interventions are being tested in trial NCT07199465?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT07199465?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07199465 being conducted?
This trial has 10 study locations across California, Colorado, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07199465's enrollment target sits among peer trials
40 1131st of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI